Table 7d. Characteristics of Miscellaneous Drugs
Last Updated: December 20, 2023
- The information in this table is derived from data on the use of these drugs for FDA-approved indications or in investigational trials. It is supplemented with data on the use of these drugs in patients with COVID-19 or MIS-C, when available.
- For dose modifications for patients with organ failure or those who require extracorporeal devices, please refer to product labels, when available.
- There are currently not enough data to determine whether certain medications can be safely coadministered with therapies for the treatment of COVID-19. When using concomitant medications with similar toxicity profiles, consider performing additional safety monitoring.
- The potential additive, antagonistic, or synergistic effects and the safety of using certain combination therapies for the treatment of COVID-19 are unknown. Clinicians are encouraged to report AEs to the FDA MedWatch program.
- For drug-drug interaction information, please refer to product labels and visit the Liverpool COVID-19 Drug Interactions website.
Dosing Regimens | Adverse Events | Monitoring Parameters | Drug-Drug Interaction Potential | Comments | |
---|---|---|---|---|---|
Fluvoxamine Not recommended by the Panel for the treatment of COVID-19 in nonhospitalized patients. | |||||
Doses for COVID-19 in Clinical Trials
|
|
|
|
| |
Intravenous Immunoglobulin Primarily used for the treatment of MIS-C. Currently under investigation in clinical trials. | |||||
Dose for MIS-C
|
|
|
|
| |
Metformin There is insufficient evidence for the Panel to recommend either for or against the use of metformin in nonhospitalized patients. Not recommended by the Panel for the treatment of COVID-19 in hospitalized patients, except in a clinical trial. | |||||
Doses for COVID-19 in Clinical Trials
|
|
|
|
| |
Key: AE = adverse event; CYP = cytochrome P450; FDA = Food and Drug Administration; IBW = ideal body weight; IV = intravenous; IVIG = intravenous immunoglobulin; MAOI = monoamine oxidase inhibitor; MIS-C = multisystem inflammatory syndrome in children; OCT = organic cation transporter; the Panel = the COVID-19 Treatment Guidelines Panel; PO = oral; TRALI = transfusion-related acute lung injury |